Arcion Going Public Via Reverse Merger
Arcion Therapeutics, a Baltimore-based biotech company focused on alleviating pain associated with diabetic neuropathy, has agreed to go public via a reverse merger with Anesiva Inc. (Nasdaq: ANSV). Simultaneously, the combined company plans to raise $20 million in new equity. Following the transaction, Arcion shareholders will hold a 64% stake. Arcion has raised over $17 million in VC funding from firms like CMEA Capital and InterWest Partners.
6 August 2009•6 mins read
